Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Oncology | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Gemzar (gemcitabine HCL)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Eli Lilly
Approval Status: Approved August 1998
Treatment Area: Lung cancer
Gemzar is indicated in combination with cisplatin for the
first-line treatment of patients with inoperable, locally advanced
(Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung
cancer. It is also indicated as first-line treatment for patients
with locally advanced (nonresectable Stage II or Stage III) or
metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is
indicated for patients previously treated with 5-FU.
Prolongation of the infusion time beyond 60 minutes and more
frequent than weekly doses have been shown to increase toxicity.
Gemzar can surpress bone marrow function as manifested by
leukopenia, thrombocytopenia and anemia. Patients should also be
monitores for myelosurpression during therapy. Gemzar can also
cause fetal harm when administered to a pregnant woman.